한글목차

세계의 핵산 약물전달 시장 규모는 2023년 11억 달러에서 예측 기간 중 20.5%의 CAGR로 추이하며, 2028년에는 27억 달러 규모로 성장할 것으로 예측됩니다.

유형별로 보면 캡슐화 부문은 2023년 6억 2,940만 달러에서 22.1%의 CAGR로 추이하며, 2028년에는 17억 달러 규모로 성장할 것으로 예측됩니다. 또한 공액 부문은 2023년 4억 3,260만 달러에서 17.9%의 CAGR로 추이하며, 2028년에는 9억 8,460만 달러 규모로 성장할 것으로 예측됩니다.

세계의 RNAi 약물전달 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, ESG 개발, 신규 기술과 새로운 개발, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약·하이라이트

제3장 시장 개요

• 핵산 의약품의 역사
• 안티센스 올리고뉴클레오티드
• RNA
• 약물전달 시스템
• 핵산 의약품
• 저해 유형
• 안티센스 올리고뉴클레오티드
• 법규제
• 전임상 INDA
• RNAi 약물전달 시장에 대한 COVID-19의 영향 분석
• COVID-19의 플러스 영향
• COVID-19의 마이너스 영향

제4장 시장 역학

• 시장 촉진요인
• 시장 억제요인
• 시장 기회

제5장 핵산 약물전달 기술 시장 : 유형별

• 캡슐화
• 바이러스 벡터 기반
• 비바이러스 벡터 기반 전달 시스템
• 공액

제6장 시장 내역 : 용도별

• 의약품 개발·발견
• RNA 기반 Drug Discovery의 프로세스
• RNAi약의 설계
• 시퀀스의 최적화
• 화학 수식
• 표적화 딜리버리
• 치료

제7장 시장 내역 : 투여 경로별

제8장 시장 내역 : 분자별

• 저분자 간섭 리보핵산
• 안티센스 올리고뉴클레오티드
• Fomivirsen(Vitravene)
• Mipomersen
• Nusinersen(Spinraza)
• Inotersen(Tegsedi)
• Eteplirsen(Exondys 51)
• Golodirsen(Vyondys 53)
• Milasen : 유니크 맞춤형 의료
• 메신저 RNA
• 기타
• 압타머
• 마이크로 RNA

제9장 시장 내역 : 치료 영역별

• 종양
• 희귀질환·유전성 질환
• 중추신경계
• 호흡기
• 기타 질병

제10장 시장 내역 : 지역별

• 북미
• 유럽
• 아시아태평양
• 일본
• 한국
• 중국
• 인도
• 호주
• 기타 지역

제11장 바이오테크놀러지 분야의 ESG(환경·사회·거버넌스)

• 바이오테크놀러지 산업에서의 주요 ESG 문제
• 바이오테크놀러지 산업의 ESG 퍼포먼스 분석
• 환경면 퍼포먼스
• 사회면 퍼포먼스
• 거버넌스면 퍼포먼스
• 바이오테크놀러지에서의 ESG : 소비자의 시점
• 사례 연구
• BCC Research에 의한 결론

제12장 새로운 기술과 개발

• 폐로의 약물전달
• 나노테크놀러지
• AI와 기계학습의 이용

제13장 임상시험·특허 분석

• 임상시험
• 특허

제14장 M&A·자금조달 전망

• 핵산 전달 기술 스타트업에 의한 자금조달

제15장 경쟁 정보

제16장 기업 개요

• ALNYLAM PHARMACEUTICALS INC.
• ARCTURUS THERAPEUTICS INC.
• ARBUTUS BIOPHARMA CORP.
• ARROWHEAD PHARMACEUTICALS INC.
• BENITEC BIOPHARMA
• CELLECTA INC.
• ELEVEN THERAPEUTICS
• GENEVANT SCIENCES CORP.
• IONIS PHARMACEUTICALS INC.
• MIRIMUS, INC.
• NOVO NORDISK
• NANODE THERAPEUTICS INC.
• OLIX PHARMACEUTICALS
• PHIO PHARMACEUTICALS CORP.
• SILENCE THERAPEUTICS PLC
• SIRNAOMICS INC.
• SOMAGENICS, INC.

영문목차

Highlights:

The global nucleic acid drug delivery market should reach $2.7 billion by 2028 from $1.1 billion in 2023 at a compound annual growth rate (CAGR) of 20.5% for the forecast period of 2023 to 2028.

Encapsulated segment of the global nucleic acid drug delivery market is expected to grow from $629.4 million in 2023 to $1.7 billion in 2028 at a CAGR of 22.1% for the forecast period of 2023 to 2028.

Conjugated segment of the global nucleic acid drug delivery market is expected to grow from $432.6 million in 2023 to $984.6 million in 2028 at a CAGR of 17.9% for the forecast period of 2023 to 2028.

Report Scope:

This research report categorizes the market for nucleic acid drugs by type. The major product segments are conjugated and encapsulated. The non-viral vectors used for encapsulation are divided into polymers, lipids and others (e.g., inorganic material, hybrid systems). The market is also segmented based on the molecule types, delivery modes and therapeutic areas. It is divided by application types into therapeutic applications and research-based applications. The markets in North America, Europe, the Asia-Pacific region and Rest of the World (RoW) are covered.

Report Includes:

• 24 data tables and 45 additional tables
• An up-to-date overview and industry analysis of the global markets for RNA interference (RNAi) drug delivery technologies
• Analyses of the global market trends, with historic market revenue (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for the RNAi drug delivery technologies market, and corresponding market share analysis based on type of RNAi, therapeutic area, and region
• Discussion of major growth drivers, industry-specific challenges, regulatory aspects, and technology advancement that will shape the market for RNAi drug delivery technologies as a basis for projecting demand in the next few years (2023-2028)
• Review of key patent grants and patent applications on RNAi drug delivery markets, and emerging technologies and new developments within the marketplace
• Latest information on the mergers and acquisition deals, partnerships, agreements, collaborations, and other strategic alliances within the marketplace
• Insight into the recent industry structure, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
• A look at commercial opportunities in the RNAi research tools and reagents, recent progress and future opportunities for RNAi therapeutics in various disease classifications, clinical trial applications, and potential markets for future developments
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, segmental revenues, and operational integration
• Descriptive company profiles of the leading global players of the industry, including Alnylam Pharmaceuticals, Benitec Biopharma, Ionis Phamaceutical, Novo Nordisk and Sirnaomics Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing the Study
• Scope of Report
• What's New in This Update?
• Research Methodology
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook

Chapter 3 Market Overview

• Introduction
• History of Nucleic Acid Drugs
• Antisense Oligonucleotides
• RNA
• Drug Delivery System
• Nucleic Acid Drugs
• Inhibition Type
• Antisense Oligonucleotide
• Regulations
• Pre-Clinical INDA
• COVID-19 Impact Analysis on the RNAi Drug Delivery Markets
• Positive Impact of COVID-19
• Negative Effect of COVID-19

Chapter 4 Market Dynamics

• Market Drivers
• Approved RNAi Drugs
• Venture Funding Increased in RNAi Drugs
• RNAi Drugs Designated as Orphan Drugs
• New Nanoparticle Technologies for Drug Delivery Systems
• Market Restraints
• High Drug Costs
• Lack of Awareness Regarding Rare Diseases
• Clustered Regularly Interspaced Short Palindromic Repeats Technology Application Growing
• Market Opportunities
• Application in Cancer Treatment
• Infectious Disease and RNAi Drugs

Chapter 5 Nucleic Acid Drug Delivery Technology Market by Type

• Encapsulation
• Viral Vector-Based
• Non-Viral Vector-Based Delivery System
• Conjugates

Chapter 6 Market Breakdown by Application

• Drug Development and Discovery
• Process of RNA-Based Drug Discovery
• Design of RNAi Drugs
• Sequence Optimization
• Chemical Modification
• Targeted Delivery
• Therapeutic Application

Chapter 7 Market Breakdown by Route of Administration

Chapter 8 Market Breakdown by Molecules

• Small Interfering Ribonucleic Acid
• Antisense Oligonucleotide
• Fomivirsen (Vitravene)
• Mipomersen
• Nusinersen (Spinraza)
• Inotersen (Tegsedi)
• Eteplirsen (Exondys 51)
• Golodirsen (Vyondys 53)
• Milasen: A Unique Personalized Medicine
• Messenger RNA
• Others
• Aptamers
• Micro RNA

Chapter 9 Market Breakdown by Therapeutic Area

• Oncology
• Rare and Genetic Diseases
• Central Nervous System
• Respiratory
• Other Disease

Chapter 10 Market Breakdown by Region

• North America
• Europe
• Asia-Pacific
• Japan
• South Korea
• China
• India
• Australia
• Rest of the World

Chapter 11 Environmental, Social and Governance in the Biotechnology Sector

• Key Environmental, Social and Governance Issues in the Biotechnology Industry
• Biotechnology Industry Environmental, Social and Governance Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Consumer Perspective on ESG in Biotechnology
• Case Study
• Concluding Remarks from BCC Research

Chapter 12 Emerging Technologies and Developments

• Drug Delivery to Lungs
• Nanotechnology
• Use of Artificial Intelligence and Machine Learning

Chapter 13 Clinical Trial and Patent Analysis

• Clinical Trials Analysis
• Patent Analysis

Chapter 14 Mergers and Acquisitions and Funding Outlook

• Start-Up Funding in Nucleic Acid Delivery Technology

Chapter 15 Competitive Intelligence

Chapter 16 Company Profiles

• ALNYLAM PHARMACEUTICALS INC.
• ARCTURUS THERAPEUTICS INC.
• ARBUTUS BIOPHARMA CORP.
• ARROWHEAD PHARMACEUTICALS INC.
• BENITEC BIOPHARMA
• CELLECTA INC.
• ELEVEN THERAPEUTICS
• GENEVANT SCIENCES CORP.
• IONIS PHARMACEUTICALS INC.
• MIRIMUS, INC.
• NOVO NORDISK
• NANODE THERAPEUTICS INC.
• OLIX PHARMACEUTICALS
• PHIO PHARMACEUTICALS CORP.
• SILENCE THERAPEUTICS PLC
• SIRNAOMICS INC.
• SOMAGENICS, INC.